Artelo Biosciences Inc (ARTL) Stock Price, Quote & News

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumat...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7049

Website: www.artelobio.com

Address:

505 Lomas Santa Fe, Suite 160, Solana Beach, United States

PennyPrince7 Feb. 1 at 9:18 PM

$ARTL

0 · Reply

Aim977 Jan. 30 at 5:56 PM

$ARTL so what was the meeting outcome

0 · Reply

ttesty Jan. 29 at 6:21 PM

$ARTL is more viable than $ENSC anyway.

0 · Reply

aim97 Jan. 29 at 1:45 PM

$ARTL board meeting tomorrow. pump it fgs

0 · Reply

ttesty Jan. 27 at 12:27 AM

Delist $ENSC and buy $ARTL.

0 · Reply

ttesty Jan. 22 at 11:46 PM

When will $PFIZER.NSE acquire $ENSC and $ARTL?

0 · Reply

ttesty Jan. 20 at 8:04 PM

$ARTL don't fall for $ENSC.

0 · Reply

ttesty Jan. 20 at 8:01 PM

Meanwhile... $ARTL is up!!

0 · Reply

ttesty Jan. 20 at 8:01 PM

Meanwhile... $ARTL is up.

0 · Reply

JayRA86 Jan. 17 at 12:53 PM

$ARTL With the delisting issue already in the background, how could the company either go against a further Nasdaq compliance rule, or not even know about it!? I’m holding onto hope both of the issues are resolved, but feeling less and less confident they will be

0 · Reply

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Nov 12, 2025, 8:00 AM EST - 2 months ago

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 8:30 AM EST - 3 months ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Oct 27, 2025, 8:00 AM EDT - 3 months ago

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Oct 15, 2025, 9:15 AM EDT - 3 months ago

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Oct 1, 2025, 4:05 PM EDT - 4 months ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Sep 30, 2025, 8:30 AM EDT - 4 months ago

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Sep 29, 2025, 7:15 PM EDT - 4 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 29, 2025, 8:30 AM EDT - 4 months ago

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Sep 5, 2025, 4:05 PM EDT - 5 months ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 4, 2025, 8:37 AM EDT - 5 months ago

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Sep 3, 2025, 11:33 AM EDT - 5 months ago

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Sep 3, 2025, 8:45 AM EDT - 5 months ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Aug 25, 2025, 7:55 AM EDT - 5 months ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Aug 13, 2025, 8:00 AM EDT - 6 months ago

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 9:15 AM EDT - 6 months ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 4, 2025, 7:30 AM EDT - 6 months ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 1, 2025, 7:45 AM EDT - 6 months ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Jul 9, 2025, 7:50 AM EDT - 7 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 8, 2025, 3:06 PM EDT - 7 months ago

Artelo Biosciences Analyst See It As An Emerging Biotech

Jul 7, 2025, 7:45 AM EDT - 7 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jun 30, 2025, 7:45 AM EDT - 7 months ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 26, 2025, 8:00 AM EDT - 7 months ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 11, 2025, 8:30 AM EDT - 8 months ago

Artelo Biosciences Announces Reverse Stock Split

Jun 5, 2025, 9:00 AM EDT - 8 months ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 2, 2025, 9:00 AM EDT - 8 months ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

May 13, 2025, 8:00 AM EDT - 9 months ago

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 28, 2025, 8:45 AM EDT - 10 months ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Mar 31, 2025, 8:30 AM EDT - 11 months ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Mar 3, 2025, 8:00 AM EST - 1 year ago

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Feb 14, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Feb 11, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Jan 13, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Dec 9, 2024, 9:15 AM EST - 1 year ago

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Nov 18, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Nov 13, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Nov 5, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Oct 9, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 15, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

Jul 3, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

May 29, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

May 13, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

Apr 23, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Apr 22, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Mar 12, 2024, 9:15 AM EDT - 2 years ago

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

PennyPrince7 Feb. 1 at 9:18 PM

$ARTL

0 · Reply

Aim977 Jan. 30 at 5:56 PM

$ARTL so what was the meeting outcome

0 · Reply

ttesty Jan. 29 at 6:21 PM

$ARTL is more viable than $ENSC anyway.

0 · Reply

aim97 Jan. 29 at 1:45 PM

$ARTL board meeting tomorrow. pump it fgs

0 · Reply

ttesty Jan. 27 at 12:27 AM

Delist $ENSC and buy $ARTL.

0 · Reply

ttesty Jan. 22 at 11:46 PM

When will $PFIZER.NSE acquire $ENSC and $ARTL?

0 · Reply

ttesty Jan. 20 at 8:04 PM

$ARTL don't fall for $ENSC.

0 · Reply

ttesty Jan. 20 at 8:01 PM

Meanwhile... $ARTL is up!!

0 · Reply

ttesty Jan. 20 at 8:01 PM

Meanwhile... $ARTL is up.

0 · Reply

JayRA86 Jan. 17 at 12:53 PM

0 · Reply

ttesty Jan. 16 at 2:19 AM

and what's 'unclever science'? Is that like mixing baking soda and vinegar and getting a chain reaction? pretty sure that's already FDA approved for consumption. $ARTL had clever science too. But it would be more clever I think to not overdose in the first place and have Narcan handy in case.

0 · Reply

rombrento Jan. 14 at 9:21 PM

$ARTL

0 · Reply

Aim977 Jan. 14 at 6:34 PM

$ARTL pump to 6 and let me get out!!

0 · Reply

Stockyoptions Jan. 14 at 6:31 PM

$ARTL slow Grind up

0 · Reply

Trapboycesar Jan. 14 at 3:01 PM

$ARTL What did I tell you my loves?

1 · Reply

ttesty Jan. 12 at 5:41 PM

All $ENSC has to do is partner with their neighbor $ARTL, make $PFE an attractive offer of $0.45/share. Then exit, Lynn retires.

0 · Reply

Trapboycesar Jan. 9 at 4:38 PM

$ARTL next week is her time

1 · Reply

MKRReformed Jan. 8 at 8:57 PM

$ARTL patent News NCP yet but worth watching

1 · Reply

PatentGrants Jan. 8 at 8:57 PM

$ARTL Artelo Biosciences has received a Notice of Allowance for a US patent titled "SOLID FORMS OF CANNABIDIOL AND USES THEREOF". https://patentcenter.uspto.gov/applications/17844544/ifw/docs

0 · Reply

JayRA86 Jan. 7 at 6:58 PM

$ARTL creeping up, surely news has to be released soon reference Nasdaq delisting? IMO It’s the only negative catalyst holding this stock back! Thoughts?

0 · Reply

stuwiatr Jan. 5 at 12:56 PM

$ARTL

0 · Reply

ttesty Jan. 4 at 12:28 PM

$ARTL catching up to $ENSC.

0 · Reply

Market Cap	3.45M
Revenue (ttm)	0.00
Net Income (ttm)	-9.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	12,991
Avg Vol	582,334
Day's Range	N/A - N/A
Shares Out	2.02M
Stochastic %K	19%
Beta	1.04
Analysts	Hold
Price Target	$18.00